New York · 2025 Regular Session · Bill
A 500: Establishes a generic drug research and development laboratory and production facility and the empire state biosimilar insulin initiative
In committee Official data
- Introduced
- In committee
- Passed one chamber
- Passed both chambers
- Enacted
Last official action: ·Record last updated:
Plain-language summary
A 500 is a bill introduced in the New York House on January 8, 2025. According to its official title, it concerns: Establishes a generic drug research and development laboratory and production facility and the empire state biosimilar insulin initiative. Primary sponsor: Phil Steck (Democratic). Most recent recorded action (January 7, 2026): REFERRED TO HEALTH.
Generated automatically from the official title, sponsor list, and status record only. It does not characterize the bill’s purpose or effects. How summaries are written
Official summary
Abstract published by the legislature (via Open States). Text as published by the legislature; reproduced verbatim.
Establishes a generic drug research and development laboratory and production facility to manufacture generic prescription drugs in the state and the empire state biosimilar insulin initiative, which will develop generic forms of the three most widely used forms of insulin.
Sponsors
Sponsors by party (alphabetical): Democratic 1
| Name | Role | Party | Chamber | District |
|---|---|---|---|---|
| Phil Steck | Primary sponsor | Democratic | House | 110 |
“Support” is shown only as formal sponsorship recorded by the legislature. Roll-call votes are available on the official bill page.
Recent official actions
- REFERRED TO HEALTH
- REFERRED TO HEALTH